Previous studies revealed that pesticides interact with α-synuclein and accelerate the rate of fibrillation. These results are consistent with the prevailing hypothesis that the direct interaction of α-synuclein with pesticides is one of many suspected factors leading to α-synuclein fibrillation and ultimately to Parkinson’s disease. In this study, the biophysical properties and fibrillation kinetics of α-synuclein in the presence of rotenone were investigated and, more specifically, the effects of rotenone on the early-stage misfolded forms of α-synuclein were considered. The thioflavine T (ThT) fluorescence assay studies provide evidence that early-phase misfolded α-synuclein forms are affected by rotenone and that the fibrillation process is accelerated. Further characterization by attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) shows that rotenone increases the amount of ordered secondary structure in this intrinsically disordered protein. Morphological characterization by transmission electron microscopy (TEM) and atomic force microscopy (AFM) provide visualization of the differences in the aggregated α-synuclein species developing during the early kinetics of the fibrillation process in the absence and presence of rotenone. We believe that these data provide useful information for a better understanding of the molecular basis of rotenone-induced misfolding and aggregation of α-synuclein.
References
[1]
Brown, R.C.; Lockwood, A.H.; Sonawane, B.R. Neurodegenerative diseases: An overview of environmental risk factors. Environ. Health Perspect. 2005, 113, 1250–1256, doi:10.1289/ehp.7567.
[2]
Findley, L.J. The economic impact of Parkinson’s disease. Parkinsonism Relat. Disord. 2007, 13, S8–S12, doi:10.1016/j.parkreldis.2007.06.003.
[3]
Uversky, V.N. Neuropathology and neurochemistry of Parkinson’s disease: The never-ending story or the story with no beginning? Minerva Psichiatr. 2009, 50, 1–26.
[4]
Uversky, V.N.; Fink, A.L. Biophysical Properties of Human Alpha-Synuclein and its Role in Parkinson’s Disease. In Recent Research Developments in Proteins; Pandalai, S.G., Ed.; Transworld Research Network: Kerala, India, 2002; pp. 153–186.
Langston, J.W.; Ballard, P.A., Jr. Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 1983, 309, 310.
[7]
Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219, 979–980.
[8]
Poskanzer, D.C.; Schwab, R.S. Cohort analysis of Parkinson’s syndrome: Evidence for a single etiology related to subclinical infection about 1920. J. Chron. Dis. 1963, 16, 961–973, doi:10.1016/0021-9681(63)90098-5.
Cory-Slechta, D.A.; Thiruchelvam, M.; Barlow, B.K.; Richfield, E.K. Developmental pesticide models of the Parkinson disease phenotype. Environ. Health Perspect. 2005, 113, 1263–1270, doi:10.1289/ehp.7570.
[12]
Rao, J.N.; Dua, V.; Ulmer, T.S. Characterization of alpha-synuclein interactions with selected aggregation-inhibiting small molecules. Biochemistry 2008, 47, 4651–4656, doi:10.1021/bi8002378.
[13]
Dauer, W.; Kholodilov, N.; Vila, M.; Trillat, A.C.; Goodchild, R.; Larsen, K.E.; Staal, R.; Tieu, K.; Schmitz, Y.; Yuan, C.A.; et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 2002, 99, 14524–14529, doi:10.1073/pnas.172514599.
[14]
Munishkina, L.A.; Fink, A.L. Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins. Biochim. Biophys. Acta 2007, 1768, 1862–1885, doi:10.1016/j.bbamem.2007.03.015.
[15]
Trojanowski, J.Q.; Lee, V.M. Parkinson’s disease and related alpha-synucleinopathies are brain amyloidoses. Ann. N. Y. Acad. Sci. 2003, 991, 107–110, doi:10.1111/j.1749-6632.2003.tb07468.x.
[16]
Stefani, M.; Dobson, C.M. Protein aggregation and aggregate toxicity: New insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. (Berl.) 2003, 81, 678–699, doi:10.1007/s00109-003-0464-5.
Baba, M.; Nakajo, S.; Tu, P.H.; Tomita, T.; Nakaya, K.; Lee, V.M.; Trojanowski, J.Q.; Iwatsubo, T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152, 879–884.
[21]
Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276, 2045–2047, doi:10.1126/science.276.5321.2045.
[22]
Zarranz, J.J.; Alegre, J.; Gomez-Esteban, J.C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atares, B.; et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55, 164–173, doi:10.1002/ana.10795.
[23]
Kruger, R.; Kuhn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S.; Przuntek, H.; Epplen, J.T.; Schols, L.; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 1998, 18, 106–108, doi:10.1038/ng0298-106.
[24]
Singleton, A.; Gwinn-Hardy, K.; Sharabi, Y.; Li, S.T.; Holmes, C.; Dendi, R.; Hardy, J.; Crawley, A.; Goldstein, D.S. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 2004, 127, 768–772, doi:10.1093/brain/awh081.
[25]
Singleton, A.B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; et al. alpha-Synuclein locus triplication causes Parkinson’s disease. Science 2003, 302, 841, doi:10.1126/science.1090278.
[26]
Farrer, M.; Kachergus, J.; Forno, L.; Lincoln, S.; Wang, D.S.; Hulihan, M.; Maraganore, D.; Gwinn-Hardy, K.; Wszolek, Z.; Dickson, D.; et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 2004, 55, 174–179, doi:10.1002/ana.10846.
[27]
Dickson, D.W. Alpha-synuclein and the Lewy body disorders. Curr. Opin. Neurol. 2001, 14, 423–432, doi:10.1097/00019052-200108000-00001.
[28]
Goedert, M. Parkinson’s disease and other alpha-synucleinopathies. Clin. Chem. Lab. Med. 2001, 39, 308–312, doi:10.1515/CCLM.2001.047.
[29]
Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2001, 2, 492–501, doi:10.1038/35081564.
[30]
Dev, K.K.; Hofele, K.; Barbieri, S.; Buchman, V.L.; van der Putten, H. Part II: Alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 2003, 45, 14–44, doi:10.1016/S0028-3908(03)00140-0.
[31]
Trojanowski, J.Q.; Lee, V.M. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: Implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch. Neurol. 1998, 55, 151–152, doi:10.1001/archneur.55.2.151.
[32]
Uversky, V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem. 2007, 103, 17–37.
[33]
Uversky, V.N.; Eliezer, D. Biophysics of Parkinson’s disease: Structure and aggregation of alpha-synuclein. Curr. Protein Pept. Sci. 2009, 10, 483–499, doi:10.2174/138920309789351921.
[34]
Santner, A.; Uversky, V.N. Metalloproteomics and metal toxicology of alpha-synuclein. Metallomics 2010, 2, 378–392, doi:10.1039/b926659c.
Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Hasegawa, M.; Goedert, M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 1998, 95, 6469–6473, doi:10.1073/pnas.95.11.6469.
[37]
Masliah, E.; Rockenstein, E.; Veinbergs, I.; Mallory, M.; Hashimoto, M.; Takeda, A.; Sagara, Y.; Sisk, A.; Mucke, L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science 2000, 287, 1265–1269, doi:10.1126/science.287.5456.1265.
[38]
Feany, M.B.; Bender, W.W. A Drosophila model of Parkinson’s disease. Nature 2000, 404, 394–398, doi:10.1038/35006074.
[39]
Giasson, B.I.; Uryu, K.; Trojanowski, J.Q.; Lee, V.M. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 1999, 274, 7619–7622, doi:10.1074/jbc.274.12.7619.
[40]
Uversky, V.N.; Li, J.; Fink, A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 2001, 276, 10737–10744, doi:10.1074/jbc.M010907200.
[41]
Uversky, V.N. Neurotoxicant-induced animal models of Parkinson’s disease: Understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 2004, 318, 225–241, doi:10.1007/s00441-004-0937-z.
[42]
Tanner, C.M.; Chen, B.; Wang, W.; Peng, M.; Liu, Z.; Liang, X.; Kao, L.C.; Gilley, D.W.; Goetz, C.G.; Schoenberg, B.S. Environmental factors and Parkinson’s disease: A case-control study in China. Neurology 1989, 39, 660–664, doi:10.1212/WNL.39.5.660.
[43]
Tanner, C.M. The role of environmental toxins in the etiology of Parkinson’s disease. Trends Neurosci. 1989, 12, 49–54, doi:10.1016/0166-2236(89)90135-5.
[44]
Di Monte, D.A. The environment and Parkinson’s disease: Is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2003, 2, 531–538, doi:10.1016/S1474-4422(03)00501-5.
[45]
McCormack, A.L.; Thiruchelvam, M.; Manning-Bog, A.B.; Thiffault, C.; Langston, J.W.; Cory-Slechta, D.A.; di Monte, D.A. Environmental risk factors and Parkinson’s disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 2002, 10, 119–127, doi:10.1006/nbdi.2002.0507.
[46]
Di Monte, D.A.; Lavasani, M.; Manning-Bog, A.B. Environmental factors in Parkinson’s disease. Neurotoxicology 2002, 23, 487–502, doi:10.1016/S0161-813X(02)00099-2.
[47]
Manning-Bog, A.B.; McCormack, A.L.; Li, J.; Uversky, V.N.; Fink, A.L.; Di Monte, D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: Paraquat and alpha-synuclein. J. Biol. Chem. 2002, 277, 1641–1644.
[48]
Ragonese, P.; Salemi, G.; Morgante, L.; Aridon, P.; Epifanio, A.; Buffa, D.; Scoppa, F.; Savettieri, G. A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson’s disease. Neuroepidemiology 2003, 22, 297–304, doi:10.1159/000071193.
[49]
Ross, G.W.; Petrovitch, H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson’s disease. Drugs Aging 2001, 18, 797–806, doi:10.2165/00002512-200118110-00001.
[50]
Ross, G.W.; Abbott, R.D.; Petrovitch, H.; Morens, D.M.; Grandinetti, A.; Tung, K.H.; Tanner, C.M.; Masaki, K.H.; Blanchette, P.L.; Curb, J.D.; et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000, 283, 2674–2679, doi:10.1001/jama.283.20.2674.
[51]
Hirsch, E.C.; Brandel, J.P.; Galle, P.; Javoy-Agid, F.; Agid, Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: An X-ray microanalysis. J. Neurochem. 1991, 56, 446–451, doi:10.1111/j.1471-4159.1991.tb08170.x.
[52]
Yasui, M.; Kihira, T.; Ota, K. Calcium, magnesium and aluminum concentrations in Parkinson’s disease. Neurotoxicology 1992, 13, 593–600.
[53]
Good, P.F.; Olanow, C.W.; Perl, D.P. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson’s disease: A LAMMA study. Brain Res. 1992, 593, 343–346, doi:10.1016/0006-8993(92)91334-B.
[54]
Gorell, J.M.; Rybicki, B.A.; Johnson, C.C.; Peterson, E.L. Occupational metal exposures and the risk of Parkinson’s disease. Neuroepidemiology 1999, 18, 303–308, doi:10.1159/000026225.
[55]
Gorell, J.M.; Johnson, C.C.; Rybicki, B.A.; Peterson, E.L.; Kortsha, G.X.; Brown, G.G.; Richardson, R.J. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson’s disease. Neurotoxicology 1999, 20, 239–247.
[56]
Altschuler, E. Aluminum-containing antacids as a cause of idiopathic Parkinson’s disease. Med. Hypotheses 1999, 53, 22–23, doi:10.1054/mehy.1997.0701.
[57]
Seidler, A.; Hellenbrand, W.; Robra, B.P.; Vieregge, P.; Nischan, P.; Joerg, J.; Oertel, W.H.; Ulm, G.; Schneider, E. Possible environmental, occupational, and other etiologic factors for Parkinson’s disease: A case-control study in Germany. Neurology 1996, 46, 1275–1284, doi:10.1212/WNL.46.5.1275.
[58]
Davis, L.E.; Adair, J.C. Parkinsonism from methanol poisoning: Benefit from treatment with anti-Parkinson drugs. Mov. Disord. 1999, 14, 520–522, doi:10.1002/1531-8257(199905)14:3<520::AID-MDS1026>3.0.CO;2-V.
[59]
Hageman, G.; van der Hoek, J.; van Hout, M.; van der Laan, G.; Steur, E.J.; de Bruin, W.; Herholz, K. Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. J. Neurol. 1999, 246, 198–206, doi:10.1007/s004150050334.
[60]
Pezzoli, G.; Strada, O.; Silani, V.; Zecchinelli, A.; Perbellini, L.; Javoy-Agid, F.; Ghidoni, P.; Motti, E.D.; Masini, T.; Scarlato, G.; et al. Clinical and pathological features in hydrocarbon-induced parkinsonism. Ann. Neurol. 1996, 40, 922–925, doi:10.1002/ana.410400616.
Klawans, H.L.; Stein, R.W.; Tanner, C.M.; Goetz, C.G. A pure parkinsonian syndrome following acute carbon monoxide intoxication. Arch. Neurol. 1982, 39, 302–304, doi:10.1001/archneur.1982.00510170044012.
[63]
Gorell, J.M.; Johnson, C.C.; Rybicki, B.A.; Peterson, E.L.; Richardson, R.J. The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998, 50, 1346–1350, doi:10.1212/WNL.50.5.1346.
[64]
Fall, P.A.; Fredrikson, M.; Axelson, O.; Granerus, A.K. Nutritional and occupational factors influencing the risk of Parkinson’s disease: A case-control study in southeastern Sweden. Mov. Disord. 1999, 14, 28–37, doi:10.1002/1531-8257(199901)14:1<28::AID-MDS1007>3.0.CO;2-O.
[65]
Semchuk, K.M.; Love, E.J.; Lee, R.G. Parkinson’s disease: A test of the multifactorial etiologic hypothesis. Neurology 1993, 43, 1173–1180, doi:10.1212/WNL.43.6.1173.
[66]
Semchuk, K.M.; Love, E.J.; Lee, R.G. Parkinson’s disease and exposure to agricultural work and pesticide chemicals. Neurology 1992, 42, 1328–1335, doi:10.1212/WNL.42.7.1328.
[67]
Liou, H.H.; Tsai, M.C.; Chen, C.J.; Jeng, J.S.; Chang, Y.C.; Chen, S.Y.; Chen, R.C. Environmental risk factors and Parkinson’s disease: A case-control study in Taiwan. Neurology 1997, 48, 1583–1588, doi:10.1212/WNL.48.6.1583.
[68]
Vanacore, N.; Nappo, A.; Gentile, M.; Brustolin, A.; Palange, S.; Liberati, A.; Di Rezze, S.; Caldora, G.; Gasparini, M.; Benedetti, F.; et al. Evaluation of risk of Parkinson’s disease in a cohort of licensed pesticide users. Neurol. Sci. 2002, 23, S119–S120, doi:10.1007/s100720200098.
[69]
Uversky, V.N.; Li, J.; Bower, K.; Fink, A.L. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: Implications for Parkinson’s disease. Neurotoxicology 2002, 23, 527–536, doi:10.1016/S0161-813X(02)00067-0.
[70]
Uversky, V.N.; Li, J.; Fink, A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: A possible factor in Parkinson’s disease. FEBS Lett. 2001, 500, 105–108, doi:10.1016/S0014-5793(01)02597-2.
[71]
Uversky, V.N.; Fink, A.L. Conformational constraints for amyloid fibrillation: The importance of being unfolded. Biochim. Biophys. Acta 2004, 1698, 131–153, doi:10.1016/j.bbapap.2003.12.008.
[72]
Uversky, V.N. Mysterious oligomerization of the amyloidogenic proteins. FEBS J. 2010, 277, 2940–2953, doi:10.1111/j.1742-4658.2010.07721.x.
[73]
Yamin, G.; Uversky, V.N.; Fink, A.L. Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett. 2003, 542, 147–152, doi:10.1016/S0014-5793(03)00367-3.
[74]
Hong, D.P.; Fink, A.L.; Uversky, V.N. Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J. Mol. Biol. 2008, 383, 214–223, doi:10.1016/j.jmb.2008.08.039.
Andre, C.; Truong, T.T.; Robert, J.F.; Guillaume, Y.C. Effect of metals on herbicides-alpha-synuclein association: A possible factor in neurodegenerative disease studied by capillary electrophoresis. Electrophoresis 2005, 26, 3256–3264, doi:10.1002/elps.200500169.
[87]
Ritz, B.; Yu, F. Parkinson’s disease mortality and pesticide exposure in California 1984–1994. Int. J. Epidemiol. 2000, 29, 323–329.
[88]
Maries, E.; Dass, B.; Collier, T.J.; Kordower, J.H.; Steece-Collier, K. The role of alpha-synuclein in Parkinson’s disease: Insights from animal models. Nat. Rev. Neurosci. 2003, 4, 727–738.
[89]
Frigerio, R.; Sanft, K.R.; Grossardt, B.R.; Peterson, B.J.; Elbaz, A.; Bower, J.H.; Ahlskog, J.E.; de Andrade, M.; Maraganore, D.M.; Rocca, W.A. Chemical exposures and Parkinson’s disease: A population-based case-control study. Mov. Disord. 2006, 21, 1688–1692, doi:10.1002/mds.21009.
[90]
Seshadri, S.; Khurana, R.; Fink, A.L. Fourier transform infrared spectroscopy in analysis of protein deposits. Methods Enzymol. 1999, 309, 559–576, doi:10.1016/S0076-6879(99)09038-2.
[91]
Barth, A.; Zscherp, C. What vibrations tell us about proteins. Q Rev. Biophys. 2002, 35, 369–430, doi:10.1017/S0033583502003815.
[92]
Haris, P.I.; Severcan, F. FTIR spectroscopic characterization of protein structure in aqueous and non-aqueous media. J. Mol. Catal. B Enzym. 1999, 7, 207–221, doi:10.1016/S1381-1177(99)00030-2.
[93]
Barth, A. The infrared absorption of amino acid side chains. Progr. Biophys. Mol. Biol. 2000, 74, 141–173, doi:10.1016/S0079-6107(00)00021-3.
[94]
Shaw, R.A.; Mantsch, H.H. Solvent influence on the conformation of cyclosporin. An FT-IR study. Can. J. Chem. 1993, 7, 1334–1339, doi:10.1139/v93-172.
Li, S.; Crooks, P.A.; Wei, X.; de Leon, J. Toxicity of dipyridyl compounds and related compounds. Crit. Rev. Toxicol. 2004, 34, 447–460, doi:10.1080/10408440490503143.
Ulmer, T.S.; Bax, A.; Cole, N.B.; Nussbaum, R.L. Structure and dynamics of micelle-bound human alpha-synuclein. J. Biol. Chem. 2005, 280, 9595–9603.
[99]
Murphy, R.M.; Tsai, A.M. Misbehaving Proteins: Protein (Mis)Folding, Aggregation, and Stability; Springer: New York, NY, USA, 2006; p. 356.
[100]
Li, N.; Ragheb, K.; Lawler, G.; Sturgis, J.; Rajwa, B.; Melendez, J.A.; Robinson, J.P. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 2003, 278, 8516–8525.
[101]
Keane, P.C.; Kurzawa, M.; Blain, P.G.; Morris, C.M. Mitochondrial dysfunction in Parkinson's disease. Parkinson's Disease 2011, 2011, Article ID 716871. 18 pages.
[102]
Sherer, T.B.; Richardson, J.R.; Testa, C.M.; Seo, B.B.; Panov, A.V.; Yagi, T.; Matsuno-Yagi, A.; Miller, G.W.; Greenamyre, J.T. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J. Neurochem. 2007, 100, 1469–1479.
[103]
Uversky, V.N.; Li, J.; Fink, A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure. J. Biol. Chem. 2011, 276, 44284–44296, doi:10.1074/jbc.M105343200.
[104]
Bernstein, S.L.; Liu, D.; Wyttenbach, T.; Bowers, M.T.; Lee, J.C.; Gray, H.B.; Winkler, J.R. Alpha-synuclein: Stable compact and extended monomeric structures and pH dependence of dimer formation. J. Am. Soc. Mass Spectrom. 2004, 15, 1435–1443, doi:10.1016/j.jasms.2004.08.003.
[105]
Byler, D.M.; Susi, H. Examination of the secondary structure of proteins by deconvolved FTIR spectra. Biopolymers 1986, 25, 469–487, doi:10.1002/bip.360250307.
[106]
Venyaminov, S.; Kalnin, N.N. Quantitative IR spectrophotometry of peptide compounds in water (H2O) solutions. I. Spectral parameters of amino acid residue absorption bands. Biopolymers 1990, 30, 1243–1257, doi:10.1002/bip.360301309.
[107]
Uversky, V.N.; Lee, H.J.; Li, J.; Fink, A.L.; Lee, S.J. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J. Biol. Chem. 2001, 276, 43495–43498.
Oberg, K.; Chrunyk, B.A.; Wetzel, R.; Fink, A.L. Nativelike secondary structure in interleukin-1 beta inclusion bodies by attenuated total reflectance FTIR. Biochemistry 1994, 33, 2628–2634, doi:10.1021/bi00175a035.
[110]
Fink, A.L.; Oberg, K.A.; Seshadri, S. Discrete intermediates versus molten globule models for protein folding: Characterization of partially folded intermediates of apomyoglobin. Fold. Des. 1998, 3, 19–25, doi:10.1016/S1359-0278(98)00005-4.
[111]
Oberg, K.A.; Fink, A.L. A new attenuated total reflectance Fourier transform infrared spectroscopy method for the study of proteins in solution. Anal. Biochem. 1998, 256, 92–106, doi:10.1006/abio.1997.2486.
[112]
Seshadri, S.; Oberg, K.A.; Fink, A.L. Thermally denatured ribonuclease A retains secondary structure as shown by FTIR. Biochemistry 1994, 33, 1351–1355, doi:10.1021/bi00172a010.
[113]
Fandrich, M.; Fletcher, M.A.; Dobson, C.M. Amyloid fibrils from muscle myoglobin. Nature 2001, 410, 165–166, doi:10.1038/35065514.
[114]
Zerovnik, E. Amyloid-fibril formation. Proposed mechanisms and relevance to conformational disease. Eur. J. Biochem. 2002, 269, 3362–3371, doi:10.1046/j.1432-1033.2002.03024.x.
[115]
Wouters, M.A.; Curmi, P.M.G. Analysis of side chain interactions and pair correlations within antiparallel b-sheets: The differences between backbone hydrogen-bonded and non-hydrrogen-bonded residue pairs. Proteins Struct. Funct. Genet. 1995, 22, 119–131, doi:10.1002/prot.340220205.
[116]
Harper, J.D.; Lansbury, P.T., Jr. Models of amyloid seeding in Alzheimer’s disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 1997, 66, 385–407, doi:10.1146/annurev.biochem.66.1.385.
[117]
Harper, J.D.; Lieber, C.M.; Lansbury, P.T., Jr. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer’s disease amyloid-beta protein. Chem. Biol. 1997, 4, 951–959, doi:10.1016/S1074-5521(97)90303-3.
[118]
Harper, J.D.; Wong, S.S.; Lieber, C.M.; Lansbury, P.T. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem. Biol. 1997, 4, 119–125, doi:10.1016/S1074-5521(97)90255-6.
Krebs, M.R.H.; Bromley, E.H.C.; Donald, A.M. The binding of thioflavin-T to amyloid fibrils: Localisation and implications. J. Struct. Biol. 2005, 149, 30–37, doi:10.1016/j.jsb.2004.08.002.
[121]
Voropai, E.S.; Samtsov, M.P.; Kaplevskii, K.N.; Maskevich, A.A.; Stepuro, V.I.; Povarova, O.I.; Kuznetsova, J.M.; Turoverov, K.K.; Fink, A.L.; Uverskii, V.N. Spectral Properties of Thioflavine T and its Complexes with Amyloid Fibrils. J. Appl. Spectrosc. 2003, 70, 868–874, doi:10.1023/B:JAPS.0000016303.37573.7e.
[122]
Munishkina, L.A.; Phelan, C.; Uversky, V.N.; Fink, A.L. Conformational behavior and aggregation of alpha-synuclein in organic solvents: Modeling the effects of membranes. Biochemistry 2003, 42, 2720–2730, doi:10.1021/bi027166s.
[123]
Nielsen, L.; Khurana, R.; Coats, A.; Frokjaer, S.; Brange, J.; Vyas, S.; Uversky, V.N.; Fink, A.L. Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry 2001, 40, 6036–6046.
[124]
Munishkina, L.A.; Cooper, E.M.; Uversky, V.N.; Fink, A.L. The effect of macromolecular crowding on protein aggregation and amyloid fibril formation. J. Mol. Recognit. 2004, 17, 456–464, doi:10.1002/jmr.699.
